NCT04965077招募中1 期
A Phase I Multicenter, Open Label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of MIL97 in Subjects With Advanced or Metastatic Solid Tumors
Beijing Mabworks Biotech Co., Ltd.1 个研究点 分布在 1 个国家目标入组 62 人开始时间: 2022年1月18日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 62
- 试验地点
- 1
- 主要终点
- The incidence of MIL97 treatment-emergent adverse events in patients with advanced or metastatic solid tumor
研究概览
简要总结
This is a Phase 1, global, multi-center, open-label, multiple-dose, first-in-human study of MIL97 to evaluate the safety, tolerability, pharmacokinetics, biomarkers and efficacy in subjects with advanced or metastatic solid tumor. The study consists of a dose escalation phase and a dose expansion phase. An accelerated titration design (cohorts 1-2 only) followed by 3+3 dose-escalation design will be used in dose escalation phase.
The starting dose for dose escalation phase is 0.01 mg/kg Q3W, followed by 5 dose cohorts (0.03mg/kg Q3W, 0.1mg/kg Q3W, 0.2mg/kg Q3W, 0.3mg/kg Q3W and 0.45mg/kg Q3W). Duration of dose limiting toxicity (DLT) observation is 21 days. Based on data of 3-week treatment regimen, one or two dose levels may be chosen for Q2w regimen. Duration of dose limiting toxicity (DLT) observation is 28 days.
One or two dose cohorts will be chosen (either 2-week regimen or 3-week regimen cohorts) to expand to total of 10 subjects in each cohort for further exploration of PK as well as safety and efficacy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult patients, >=18 years of age;
- •Diagnosis of Refractory/relapsed metastatic and/or unresectable solid tumors;
- •At least one extracranial measurable unirradiated lesion or evaluable lesion (recist v1.1) ;
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1Life expectancy >=3 months;
- •Sufficient organ and bone marrow function within 7 days before enrollment;
- •Life expectancy >=12 weeks;
- •Able and willing to provide written informed consent and to comply with the study protocol.
排除标准
- •have a history of myocardial infarction within 6 months or a history of arterial thromboembolic event within 3 months before the first dose;
- •Comorbidity that would interfere with therapy, including interstitial pneumonia, symptomatic congestive heart failure; unstable angina, uncontrolled hypertension; ongoing cardiac arrhythmia ≥ CTCAE 5.0 Grade 3, active coagulopathy, uncontrolled diabetes, QTcF>450ms (Male) or QTcF>470ms (Female) at screening;
- •Patients have a known or suspected history of an autoimmune disorder, except for the following: Type 1 diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders such as vitiligo, or alopecia not requiring systemic therapy, or conditions not expected to recur in the absence of an external trigger are eligible;
- •Have a history of manifested central nervous system (CNS) metastases or have primary brain tumor. Patients with known or suspected leptomeningeal disease or cord compression;
- •Receipt of allograft or allogeneic hematopoietic stem cell transplantation;
- •Patients have another active invasive malignancy, but history of a non-invasive malignancy and history of malignancy that is in complete remission after treatment with curative intent are allowed;
- •Active known clinically serious infections are required intravenous antibiotic treatment;
- •Have a history of primary immunodeficiency, including but not limited with human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness;
- •Active and clinical significant bacterial, fungal, or viral infection including hepatitis B virus (HBV) or hepatitis C (HCV) (Hepatitis B should be confirmed as HBV surface antigen (HBsAg) positive or HBV core antibody (HBcAb) positive with HBV DNA above ULN);
- •Any antitumor therapy within prior 4 weeks (including chemotherapy, targeted therapy, hormone therapy, immunotherapy, radiotherapy, tumor embolization, etc), except for palliative radiotherapy for relief bone pain;
- •Major surgery within prior 4 weeks or expected to require major surgery during study treatment (Major surgery: laparotomy, thoracotomy, and internal organs excision by laparoscopic surgery);
- •Patients have concurrent received or used an immunosuppressive agent within 14 days before study treatment, with the following exceptions and notes: Systemic steroids at physiologic doses, intranasal, inhaled, topical, intra-articular, and ocular corticosteroids with minimal systemic absorption, transient courses of steroids may be approved by the Medical Monitor;
- •Previous exposure to CD40 antibodies;
- •Patients received a live attenuated vaccine within 28 days before study treatment and plan to receive live vaccines during the study unless approved by both investigator and sponsor;
- •Toxicities due to prior therapy are unresolved to ≤ CTCAE 5.0 Grade 1 except for AEs not constituting a safety risk to the patient based on the judgment of investigators;
- •History of clinically significant sensitivity or allergy to MIL97, their excipients, or intravenous gamma globulin;
- •Females who are pregnant or lactating or who intend to become pregnant during the clinical trial period and within 6 months after discontinuation of study treatment. Female or Male who refused using birth control during the clinical trial period and within 6 months after discontinuation of study treatment;
- •Participation in a therapeutic clinical study within 4 weeks for biological treatments, and within 1 week or 5 half-lives for small-molecule agents, before study drug treatment, or current participation in other therapeutic investigational procedures;
- •Patients who have any clinically significant psychiatric, social, or medical condition that, in the opinion of the investigator, could increase the patient's risk, interfere with protocol adherence, or affect the patient's ability to give informed consent are ineligible to participate in the study.
研究组 & 干预措施
MIL97
Experimental
干预措施: Recombinant Humanized Monoclonal Antibody MIL97 for Injection (Drug)
结局指标
主要结局
The incidence of MIL97 treatment-emergent adverse events in patients with advanced or metastatic solid tumor
时间窗: up to 2.5 year after enrollment
incidence of AEs and SAEs assessed by NCI CTCAE v5.0.
次要结局
- Pharmacokinetics: Cmax;(up to 1.5 year after enrollment)
- Pharmacokinetics: AUC(up to 1.5 year after enrollment)
- Objective response rate (ORR);(up to 2.5 year after enrollment)
- Duration of response (DoR);(up to 2.5 year after enrollment)
- Progression free survival (PFS);(up to 2.5 year after enrollment)
- The overall survival for patients with advanced or metastatic solid tumor;(up to 2.5 year after enrollment)
- The Disease control rate for patients with advanced or metastatic solid tumor;(up to 2.5 year after enrollment)
- Immunogenicity;(up to 2.5 year after enrollment)
- Biomarkers;(up to 2.5 year after enrollment)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple MyelomaRefractory Multiple MyelomaRelapsed Multiple MyelomaNCT04434469Genentech, Inc.27
暂停
1 期
IMM2902, a HER2/SIRPα Bispecific MAb-Trap Antibody-receptor Fusion Protein, in Patients with HER2-expressing Advanced Solid TumorsAdvanced Solid TumorAdvanced Gastric CancerAdvanced Breast CancerNCT05076591ImmuneOnco Biopharmaceuticals (Shanghai) Inc.135
终止
1 期
Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.Advanced Solid TumorRAS MutationRAF MutationNF1 MutationNCT05831995ABM Therapeutics Corporation12
Unknown
1 期
Phase 1 Study of F182112 in Patients With Relapsed or Refractory Multiple MyelomaDose-Escalation Study, Relapsed or Refractory Multiple MyelomaNCT04984434Shandong New Time Pharmaceutical Co., LTD68
已完成
1 期
First-In-Human Study in Subjects With Advanced or Metastatic Solid Malignant TumorsAdvanced Solid TumorsMetastatic Solid TumorsNCT05494918Alphamab (Australia) Co Pty Ltd.62